Develops drugs for rare diseases.
Dec 2023Revenue CHF 379/yrExpenses CHF 6.58M/yr
No trendCash runway ≈ 1 month from Dec 2023
Figures by year
When will Altamira Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2023, revenue was CHF 379 and expenses CHF 6.58M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2023 | CHF 379 | CHF 6.58M | −CHF 6.58M |
| Dec 2022 | CHF 306K | CHF 19.2M | −CHF 18.9M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.